Personalized Medicine

The aim of this project was to present several therapies and possible applications of these in the field of personalized medicine along with the production techniques and workflows surrounding them. There are two main categories; cell therapies and non-cell therapies. Cell therapies utilize the body's own T cells and immune system, and non-cell therapies are mostly based on proteins and nucleotides. All of these applications face different challenges that need to be overcome to be considered effective treatments and they all have a high production cost. The report also presents differences and similarities of manufacturing models that are specifically used in the production of cell therapies. It could be argued that these manufacturing models can be adjusted and work for both cell therapies and non-cell therapies. Three different workflows for three different personalized medicines, antibody drug conjugates (ADCs), tumor infiltrating lymphocytes (TILs) and mRNA vaccines, are presented in this report. Technologies and processes valuable to the manufacturing process were also presented, including bioreactors, interleukin 2 media and cell dissociation technologies. In conclusion, there are methods and techniques that are frequently used in production that are, or possibly could be useful for manufacturing personalized drug components. Production of products used in personalized medicine is possible if the right resources are available. Personalized therapies are presently most commonly applied to cancer diseases but there are developments for these therapies that could benefit several other diseases. To fully apply personalized therapies to these diseases further studies on suitable biomarkers and targets in drugs are needed. Overall, personalized medicine has promising possibilities in treatments for many types of complex diseases. This project was assigned by Cytiva which is a global life science company and the product order can be seen in the appendix

Personalized Medicine

The aim of this project was to present several therapies and possible applications of these in the field of personalized medicine along with the production techniques and workflows surrounding them. There are two main categories; cell therapies and non-cell therapies. Cell therapies utilize the body's own T cells and immune system, and non-cell therapies are mostly based on proteins and nucleotides. All of these applications face different challenges that need to be overcome to be considered effective treatments and they all have a high production cost. The report also presents differences and similarities of manufacturing models that are specifically used in the production of cell therapies. It could be argued that these manufacturing models can be adjusted and work for both cell therapies and non-cell therapies. Three different workflows for three different personalized medicines, antibody drug conjugates (ADCs), tumor infiltrating lymphocytes (TILs) and mRNA vaccines, are presented in this report. Technologies and processes valuable to the manufacturing process were also presented, including bioreactors, interleukin 2 media and cell dissociation technologies. In conclusion, there are methods and techniques that are frequently used in production that are, or possibly could be useful for manufacturing personalized drug components. Production of products used in personalized medicine is possible if the right resources are available. Personalized therapies are presently most commonly applied to cancer diseases but there are developments for these therapies that could benefit several other diseases. To fully apply personalized therapies to these diseases further studies on suitable biomarkers and targets in drugs are needed. Overall, personalized medicine has promising possibilities in treatments for many types of complex diseases. This project was assigned by Cytiva which is a global life science company and the product order can be seen in the appendix